DIRA Efficacy

KINERET efficacy in DIRA patients

In a long-term study, KINERET was demonstrated to induce remission in patients with DIRA1

Two overlapping squares that are transparent

Remission criteria:

CRP ≤5 mg/L, no pustulosis, no inflammatory bone disease (no evidence of bone inflammation shown in imaging [bone scans, x-rays, or MRIs] such as osteomyelitis/periostitis, or no clinical evidence of bone pain or bone swelling [in which case no bone imaging was performed]), no concomitant glucocorticosteroid use1,2

  • The median time to the first documented inflammatory remission was 15 months2
  • All patients were able to discontinue glucocorticosteroid treatment2
Study Design: Clinical efficacy and safety were determined by a long-term natural history study including 9 DIRA patients (aged 1 month-9 years at the start of KINERET treatment).1
  • Primary endpoints included the proportion of patients during the first KINERET treatment period who achieved inflammatory remission at 6 months, 12 months, and at the final National Institutes of Health visit1
  • Initial KINERET dose was 1 to 2 mg/kg/day in the 6 patients for which the dose was reported. The dose was then individually adjusted to reach a stable efficacious dose2
  • The highest KINERET dose studied was 7.5 mg/kg/day. At the last visit during the first KINERET treatment period, the dose ranged between 2.2 and 6.1 mg/kg/day2
  • The duration of treatment with KINERET was up to 10 years2